Associate Professor
Emory Medical School / Georgia Tech
James Dahlman is the McCamish Early Career Professor in the Department of Biomedical Engineering at Georgia Tech and Emory School of Medicine. His lab works at the interface of chemical engineering, genomics, and gene editing by applying big data approaches to nanomedicine. His lab is known for developing DNA barcoded nanoparticles to measure how hundreds of nanoparticles deliver mRNA and siRNA in multiple cell types from a single animal in vivo. The lab uses these approaches to deliver RNA outside the liver.
James was a co-founder and Board Chairman of Guide Therapeutics, which was acquired by Beam Therapeutics. His trainees have become venture capitalists, started independent research labs, and work in some of the most cutting-edge organizations in RNA therapeutics. James received his Ph.D. in 2015 from the Harvard-MIT HST Program, where he studied with Robert Langer, and as a post-doc, studied CRISPR-Cas9 with Feng Zhang.
Monday, July 24, 2023
1:00 PM – 5:00 PM US PST
